SI
Neutral signalScored 2026-09-16 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Research, not advice.
À propos
Shoulder Innovations, Inc.
- Nom
- Shoulder Innovations, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Specialties
- Bourse
- NYSE
- Capitalisation
- $409.3M
- Employés
- 74
- PDG
- Robert Joseph Ball
- Site web
- http://www.shoulderinnovations.com
- Marché
- AARDASMBENTAEPRXINGNMDXH
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 32 675 titres (~651 797,37 $ US)
- Insiders
- Ball Robert JosephAhearn Matthew Fraser
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$389,019
Avg sell (VWAP, 90d window) $19.36 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$201,312 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-14
- Last synced
-
2026-09-20 09:54:07
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-14 | Ball Robert Joseph | Sell · S | 10,175 | $18.45 | $187,706 | Form 4 |
| 2026-08-18 | Ahearn Matthew Fraser | Sell · S · 10b5-1 | 1,600 | $21.38 | $34,211 | Form 4 |
| 2026-08-17 | Ahearn Matthew Fraser | Sell · S · 10b5-1 | 8,314 | $20.10 | $167,101 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-11-08 | Chris Jacobs | Sale (Full) | $1,001 - $15,000 |
| 2022-07-18 | Chris Jacobs | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-16 Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
SI presents a meaningful event-driven catalyst stack (FDA clearance, 56% YoY revenue growth, new partnership, patent settlement) with a solid catalyst score of 65, but the severely distressed fundamentals (persistent…
The first sentence of the analysis written for SI on 2026-09-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: Congress, fundamentals. Moteurs : Congrès, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 11.07 · operating margin -56% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Gross Profit Margin | 76.5% | 77.0% | 79.2% | |
| Ebit Margin | -85.1% | -45.2% | -61.7% | |
| Ebitda Margin | -78.4% | -38.3% | -53.2% | |
| Operating Profit Margin | -55.6% | -46.3% | -56.4% | |
| Pretax Profit Margin | -85.3% | -49.4% | -65.7% | |
| Continuous Operations Profit Margin | -85.3% | -49.4% | -65.7% | |
| Net Profit Margin | -85.3% | -49.4% | -65.7% | |
| Bottom Line Profit Margin | -85.3% | -49.4% | -65.7% | |
| Current Ratio | 11.072 | 4.593 | 11.172 | |
| Quick Ratio | 9.551 | 2.768 | 8.855 | |
| Solvency Ratio | -1.274 | -0.137 | -0.117 | |
| Cash Ratio | 1.893 | 0.801 | 1.456 | |
| Price To Earnings Ratio | -7.296 | -19.545 | -23.889 | |
| Price To Earnings Growth Ratio | -0.047 | -0.880 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.047 | -0.880 | 0.000 | |
| Price To Earnings Diluted Ratio | -7.296 | -19.545 | -23.889 | |
| Price To Earnings Diluted Growth Ratio | -0.047 | -0.880 | 0.000 | |
| Price To Book Ratio | 2.096 | -5.482 | -7.546 | |
| Price To Sales Ratio | 6.234 | 9.482 | 15.557 | |
| Price To Free Cash Flow Ratio | -8.189 | -16.513 | -18.868 | |
| Price To Operating Cash Flow Ratio | -10.310 | -21.201 | -22.813 | |
| Debt To Assets Ratio | 0.088 | 0.342 | 0.266 | |
| Debt To Equity Ratio | 0.107 | -0.269 | -0.364 | |
| Debt To Capital Ratio | 0.096 | -0.369 | -0.572 | |
| Long Term Debt To Capital Ratio | 0.096 | -0.366 | -0.565 | |
| Financial Leverage Ratio | 1.207 | -0.788 | -1.366 | |
| Working Capital Turnover Ratio | 0.555 | 0.890 | 0.000 | |
| Operating Cash Flow Ratio | -2.016 | -1.849 | -3.069 | |
| Operating Cash Flow Sales Ratio | -0.605 | -0.447 | -0.682 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.259 | 1.284 | 1.209 | |
| Debt Service Coverage Ratio | -529.729 | -9.200 | -13.473 | |
| Interest Coverage Ratio | -375.671 | -11.134 | -14.276 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.904 | -0.960 | -0.909 | |
| Capital Expenditure Coverage Ratio | -3.862 | -3.523 | -4.783 | |
| Dividend Paid And Capex Coverage Ratio | -3.862 | -3.523 | -4.783 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -7.636 | -25.477 | -30.048 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 76.5% | ▼-0.5% | ▼-1.1% |
| Ebit Margin | -85.2% | ▼-39.9% | ▼-21.1% |
| Ebitda Margin | -78.4% | ▼-40.1% | ▼-21.8% |
| Operating Profit Margin | -55.6% | ▼-9.2% | ▼-2.8% |
| Pretax Profit Margin | -85.3% | ▼-35.9% | ▼-18.5% |
| Continuous Operations Profit Margin | -85.3% | ▼-35.9% | ▼-18.5% |
| Net Profit Margin | -85.3% | ▼-35.9% | ▼-18.5% |
| Bottom Line Profit Margin | -85.3% | ▼-35.9% | ▼-18.5% |
| Current Ratio | 11.072 | ▲6.479 | ▲2.126 |
| Quick Ratio | 9.551 | ▲6.782 | ▲2.493 |
| Solvency Ratio | -1.274 | ▼-1.137 | ▼-0.765 |
| Cash Ratio | 1.893 | ▲1.092 | ▲0.510 |
| Price To Earnings Ratio | -7.296 | ▲12.249 | ▲9.614 |
| Price To Earnings Growth Ratio | -0.047 | ▲0.832 | ▲0.262 |
| Forward Price To Earnings Growth Ratio | -0.047 | ▲0.832 | ▲0.262 |
| Price To Earnings Diluted Ratio | -7.296 | ▲12.249 | ▲9.614 |
| Price To Earnings Diluted Growth Ratio | -0.047 | ▲0.832 | ▲0.262 |
| Price To Book Ratio | 2.096 | ▲7.578 | ▲5.740 |
| Price To Sales Ratio | 6.234 | ▼-3.248 | ▼-4.190 |
| Price To Free Cash Flow Ratio | -8.189 | ▲8.324 | ▲6.334 |
| Price To Operating Cash Flow Ratio | -10.310 | ▲10.892 | ▲7.798 |
| Debt To Assets Ratio | 0.088 | ▼-0.254 | ▼-0.144 |
| Debt To Equity Ratio | 0.107 | ▲0.376 | ▲0.282 |
| Debt To Capital Ratio | 0.096 | ▲0.465 | ▲0.378 |
| Long Term Debt To Capital Ratio | 0.096 | ▲0.462 | ▲0.374 |
| Financial Leverage Ratio | 1.207 | ▲1.995 | ▲1.523 |
| Working Capital Turnover Ratio | 0.555 | ▼-0.335 | ▲0.073 |
| Operating Cash Flow Ratio | -2.016 | ▼-0.166 | ▲0.296 |
| Operating Cash Flow Sales Ratio | -0.605 | ▼-0.157 | ▼-0.027 |
| Free Cash Flow Operating Cash Flow Ratio | 1.259 | ▼-0.025 | ▲0.008 |
| Debt Service Coverage Ratio | -529.729 | ▼-520.529 | ▼-345.595 |
| Interest Coverage Ratio | -375.671 | ▼-364.537 | ▼-241.977 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -1.904 | ▼-0.944 | ▼-0.647 |
| Capital Expenditure Coverage Ratio | -3.862 | ▼-0.340 | ▲0.194 |
| Dividend Paid And Capex Coverage Ratio | -3.862 | ▼-0.340 | ▲0.194 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -7.636 | ▲17.842 | ▲13.418 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Market cap | $295.0M | $299.8M | $299.8M | |
| Enterprise value | $283.1M | $308.5M | $308.1M | |
| EV / Sales | 5.98x | 9.75x | 15.98x | |
| EV / Op. cash flow | -9.90x | -21.81x | -23.44x | |
| EV / Free cash flow | -7.86x | -16.99x | -19.39x | |
| EV / EBITDA | -7.64x | -25.48x | -30.05x | |
| Net debt / EBITDA | 0.32x | -0.71x | -0.80x | |
| Current ratio | 11.07x | 4.59x | 11.17x | |
| Income quality | 0.71x | 0.91x | 1.04x | |
| Graham net-net | $5 | -$4 | -$3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.2% | 109.2% | 106.4% | |
| Working capital | $143.0M | $27.5M | $43.6M | |
| Invested capital | $155.7M | $35.4M | $50.0M | |
| Return on assets | -23.8% | -36.3% | -23.3% | |
| Operating ROA | -24.7% | -30.1% | 0.0% | |
| Return on tangible assets | -23.8% | -36.6% | -23.6% | |
| Return on equity | -28.7% | 28.6% | 31.8% | |
| Return on invested capital | -16.9% | -41.3% | -21.7% | |
| Return on capital employed | -16.9% | -41.4% | -21.7% | |
| Earnings yield | -13.7% | -5.2% | -4.2% | |
| Free cash flow yield | -12.2% | -6.1% | -5.3% | |
| Capex / Op. cash flow | -25.9% | -28.4% | -20.9% | |
| Capex / Depreciation | 230.9% | 182.8% | 167.5% | |
| Capex / Sales | 15.7% | 12.7% | 14.3% | |
| SG&A / Sales | 115.7% | 109.1% | 119.9% | |
| R&D / Sales | 16.3% | 14.2% | 15.7% | |
| Stock comp / Sales | 2.1% | 2.4% | 2.3% | |
| Intangibles / Total assets | 0.1% | 0.9% | 1.3% | |
| Days sales outstanding | 64d | 59d | 89d | |
| Days payables outstanding | 291d | 244d | 179d | |
| Operating cycle | 773d | 759d | 993d | |
| Cash conversion cycle | 481d | 515d | 815d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-1.6%EV / Sales ▼-38.7%EV / EBITDA ▲+70.0%EV / Op. cash flow ▲+11.914Earnings yield ▼-0.085
Profitability
Return on equity ▼-0.572Return on assets ▲+0.125Return on invested capital ▲+0.244Return on capital employed ▲+0.245Operating ROA ▲+0.054Income quality ▼-0.197Tax burden 0.000
Efficiency
Days sales outstanding ▲+4.659Days payables outstanding ▲+47.808Operating cycle ▲+14.201Cash conversion cycle ▼-33.607Capex / Sales ▲+0.030R&D / Sales ▲+0.021
Balance-sheet strength
Current ratio ▲+6.479Net debt / EBITDA ▲+1.030Working capital ▲+115492000.000Invested capital ▲+120279000.000Intangibles / Total assets ▼-0.009
Change over 5 years
Valuation
Market cap ▼-1.6%EV / Sales ▼-62.6%EV / EBITDA ▲+74.6%EV / Op. cash flow ▲+13.543Earnings yield ▼-0.095
Profitability
Return on equity ▼-0.605Return on assets ▼-0.004Return on invested capital ▲+0.048Return on capital employed ▲+0.048Operating ROA n/aIncome quality ▼-0.330Tax burden 0.000
Efficiency
Days sales outstanding ▼-25.095Days payables outstanding ▲+112.829Operating cycle ▼-220.648Cash conversion cycle ▼-333.476Capex / Sales ▲+0.014R&D / Sales ▲+0.007
Balance-sheet strength
Current ratio ▼-0.100Net debt / EBITDA ▲+1.122Working capital ▲+99405000.000Invested capital ▲+105701000.000Intangibles / Total assets ▼-0.012
Employee count
Peer market caps
Recent news
- 2026-09-19 Squarepoint Ops LLC Invests $896,000 in Shoulder Innovations, Inc. $SI Squarepoint Ops LLC purchased a new position in shares of Shoulder Innovations, Inc. (NYSE: SI) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 44,159 shares of the company''s stock, valued at approximately $896,000. Squarepoint Ops LLC owned about 0.21%
- 2026-09-16 Shoulder Innovations, Inc. (SI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Shoulder Innovations, Inc. (SI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-10 Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch Second Product Introduction on New Line of Technologies for Metal-Sensitive Patients GRAND RAPIDS, Mich., Sept. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the N-22 Humeral Head, a titanium implant option for patients with metal hypersensitivity.
- 2026-09-09 Shoulder Innovations Announces Exclusive Partnership with ALM Ortho to Introduce Bespoke Solution for Complex Shoulder Reconstruction Procedures GRAND RAPIDS, Mich., Sept. 9, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has entered into an exclusive collaboration with ALM Ortho, Inc. ("ALM Ortho"), a leader in additive manufacturing of titanium orthopedic implants, to introduce a bespoke implant for the treatment of severe shoulder deformity and other highly complex revision cases, circumstances for which no adequate solution currently exists.
- 2026-09-08 Shoulder Innovations Announces Settlement of Patent Litigation with Catalyst OrthoScience GRAND RAPIDS, Mich., Sept. 8, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that it has entered into a settlement agreement with Catalyst OrthoScience Inc. ("Catalyst") to resolve all outstanding patent litigation between the two companies.
- 2026-09-01 Shoulder Innovations to Participate in the Morgan Stanley 24th Annual Healthcare Conference GRAND RAPIDS, Mich., Sept. 1, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that members of management will participate in a fireside chat at the Morgan Stanley 24th Annual Healthcare Conference.
- 2026-08-10 Shoulder Innovations Promotes Jon Osborne to Chief Commercial Officer GRAND RAPIDS, Mich., Aug. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the promotion of Jon Osborne to Chief Commercial Officer, effective August 6, 2026.
- 2026-08-09 Shoulder Innovations Q2 Earnings Call Highlights Shoulder Innovations NYSE: SI reported second-quarter net revenue of $17.2 million, up 56% from $11 million a year earlier, as the company added surgeons, expanded use among existing customers and advanced several product launches. The company raised its full-year 2026 revenue outlook to $67 million to $69 million, from a prior range of $65 million to $68 million.
- 2026-08-06 Shoulder Innovations, Inc. (SI) Q2 2026 Earnings Call Transcript Shoulder Innovations, Inc. (SI) Q2 2026 Earnings Call Transcript
- 2026-08-06 Shoulder Innovations, Inc. (SI) Reports Q2 Loss, Beats Revenue Estimates Shoulder Innovations, Inc. (SI) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to a loss of $64.47 per share a year ago.